Effects of a sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of huntington’s disease

International Journal of Molecular Sciences

Volumn 18, Issue 4, 2017, Pages

  Valdeolivas, Sara ^a,b,c   Sagredo, Onintza ^a,b,c   Delgado, Mercedes ^a,d   Pozo, Miguel A ^a   Fernández Ruiz, Javier ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Basal ganglia; Cannabidiol; Huntington s disease; Neuroprotection; Phytocannabinoids; R6 2 mice; 9 tetrahydrocannabinol

Indexed keywords

CANNABICHROMENE; CANNABINOID; CHOLINE; FLUORODEOXYGLUCOSE F 18; GLUTAMIC ACID; LACTIC ACID; N ACETYLASPARTIC ACID; NABIXIMOLS; TAU PROTEIN; PLANT EXTRACT; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUDIOMETRY; BASAL GANGLION; BEHAVIOR; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DORSAL STRIATUM; DYSTONIA; EXCITOTOXICITY; GLOBUS PALLIDUS; HUNTINGTON CHOREA; MALE; METABOLIC ACTIVITY ASSAY; MOTOR ACTIVITY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; ROTAROD TEST; STRIATE CORTEX; ANIMAL; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DRUG EFFECTS; LOCOMOTION; METABOLISM; MITOCHONDRION;

ANIMALS; BASAL GANGLIA; CANNABINOIDS; CORPUS STRIATUM; HUNTINGTON DISEASE; LOCOMOTION; MICE; MITOCHONDRIA; PLANT EXTRACTS;

EID: 85016160980     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18040684     Document Type: Article

References (40)

1. Roze, E.; Bonnet, C.; Betuing, S.; Caboche, J. Huntington’s disease. Adv. Exp. Med. Biol. 2010, 685, 45–63. [PubMed]
2. Zuccato, C.; Valenza, M.; Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol. Rev. 2010, 90, 905–981. [CrossRef] [PubMed]
3. Johnson, C.D.; Davidson, B.L. Huntington’s disease: Progress toward effective disease-modifying treatments and a cure. Hum. Mol. Genet. 2010, 19, R98–R102. [CrossRef] [PubMed]
4. López-Sendón Moreno, J.L.; García Caldentey, J.; Trigo Cubillo, P.; Ruiz Romero, C.; García Ribas, G.; Alonso Arias, M.A.; García de Yébenes, M.J.; Tolón, R.M.; Galve-Roperh, I.; Sagredo, O.; et al. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J. Neurol. 2016, 263, 1390–1400. [PubMed]
5. Pazos, M.R.; Sagredo, O.; Fernández-Ruiz, J. The endocannabinoid system in Huntington’s disease. Curr. Pharm. Des. 2008, 14, 2317–2325. [CrossRef] [PubMed]
6. Fernández-Ruiz, J.; García, C.; Sagredo, O.; Gómez-Ruiz, M.; de Lago, E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin. Ther. Targets 2010, 14, 387–404. [CrossRef] [PubMed]
7. Lastres-Becker, I.; Bizat, N.; Boyer, F.; Hantraye, P.; Fernández-Ruiz, J.; Brouillet, E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 2004, 15, 2375–2379. [CrossRef] [PubMed]
8. Sagredo, O.; Ramos, J.A.; Decio, A.; Mechoulam, R.; Fernández-Ruiz, J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur. J. Neurosci. 2007, 26, 843–851. [CrossRef] [PubMed]
9. Valdeolivas, S.; Navarrete, C.; Cantarero, I.; Bellido, M.L.; Muñoz, E.; Sagredo, O. Neuroprotective properties of cannabigerol in Huntington’s disease: Studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 2015, 12, 185–199. [CrossRef] [PubMed]
10. Blázquez, C.; Chiarlone, A.; Sagredo, O.; Aguado, T.; Pazos, M.R.; Resel, E.; Palazuelos, J.; Julien, B.; Salazar, M.; Börner, C.; et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain 2011, 134, 119–136. [CrossRef] [PubMed]
11. Palazuelos, J.; Aguado, T.; Pazos, M.R.; Julien, B.; Carrasco, C.; Resel, E.; Palazuelos, J.; Julien, B.; Salazar, M.; Börner, C.; et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 2009, 132, 3152–3164. [CrossRef] [PubMed]
12. Sagredo, O.; González, S.; Aroyo, I.; Pazos, M.R.; Benito, C.; Lastres-Becker, I.; Romero, J.P.; Tolón, R.M.; Mechoulam, R.; Brouillet, E.; et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington’s disease. Glia 2009, 57, 1154–1167. [CrossRef] [PubMed]
13. Pintor, A.; Tebano, M.T.; Martire, A.; Grieco, R.; Galluzzo, M.; Scattoni, M.L.; Pèzzola, A.; Coccurello, R.; Felici, F.; Cuomo, V.; et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 2006, 51, 1004–1012. [CrossRef] [PubMed]
14. Dowie, M.J.; Howard, M.L.; Nicholson, L.F.; Faull, R.L.; Hannan, A.J.; Glass, M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington’s disease transgenic mice. Neuroscience 2010, 170, 324–336. [CrossRef] [PubMed]
15. Sastre-Garriga, J.; Vila, C.; Clissold, S.; Montalban, X. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis. Expert Rev. Neurother. 2011, 11, 627–637. [PubMed]
16. Zajicek, J.P.; Apostu, V.I. Role of cannabinoids in multiple sclerosis. CNS Drugs 2011, 25, 187–201. [CrossRef] [PubMed]
17. Pertwee, R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 2009, 156, 397–411. [CrossRef] [PubMed]
18. Sagredo, O.; Pazos, M.R.; Satta, V.; Ramos, J.A.; Pertwee, R.G.; Fernández-Ruiz, J. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease. J. Neurosci. Res. 2011, 89, 1509–1518. [CrossRef] [PubMed]
19. Lastres-Becker, I.; Bizat, N.; Boyer, F.; Hantraye, P.; Brouillet, E.; Fernández-Ruiz, J. Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate. Neuroreport 2003, 14, 813–816. [CrossRef] [PubMed]
20. Valdeolivas, S.; Satta, V.; Pertwee, R.G.; Fernández-Ruiz, J.; Sagredo, O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: Role of CB1 and CB2 receptors. ACS Chem. Neurosci. 2012, 3, 400–406. [PubMed]
21. Jiménez-Xarrié, E.; Davila, M.; Gil-Perotín, S.; Jurado-Rodríguez, A.; Candiota, A.P.; Delgado-Mederos, R.; Lope-Piedrafita, S.; García-Verdugo, J.M.; Arús, C.; Martí-Fàbregas, J. In vivo and ex vivo magnetic resonance spectroscopy of the infarct and the subventricular zone in experimental stroke. J. Cereb. Blood Flow Metab. 2015, 35, 828–834. [CrossRef] [PubMed]
22. Pazos, M.R.; Mohammed, N.; Lafuente, H.; Santos, M.; Martínez-Pinilla, E.; Moreno, E.; Valdizan, E.; Romero, J.; Pazos, A.; Franco, R.; et al. Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors. Neuropharmacology 2013, 71, 282–291. [PubMed]
23. Lafuente, H.; Pazos, M.R.; Alvarez, A.; Mohammed, N.; Santos, M.; Arizti, M.; Alvarez, F.J.; Martinez-Orgado, J.A. Effects of cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-ischemia. Front. Neurosci. 2016, 10, 323. [CrossRef] [PubMed]
24. Tsang, T.M.; Woodman, B.; McLoughlin, G.A.; Griffin, J.L.; Tabrizi, S.J.; Bates, G.P.; Holmes, E. Metabolic characterization of the R6/2 transgenic mouse model of Huntington’s disease by high-resolution MAS 1H NMR spectroscopy. J. Proteome Res. 2006, 5, 483–492. [PubMed]
25. 1H NMR based metabolomics of CSF and blood serum: A metabolic profile for a transgenic rat model of Huntington disease. Biochim. Biophys. Acta 2011, 1812, 1371–1379. [CrossRef] [PubMed]
26. Heikkinen, T.; Lehtimäki, K.; Vartiainen, N.; Puoliväli, J.; Hendricks, S.J.; Glaser, J.R.; Bradaia, A.; Wadel, K.; Touller, C.; Kontkanen, O.; et al. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington’s disease. PLoS ONE 2012, 7, e50717. [CrossRef] [PubMed]
27. Wegrzynowicz, M.; Bichell, T.J.; Soares, B.D.; Loth, M.K.; McGlothan, J.S.; Mori, S.; Alikhan, F.S.; Hua, K.; Coughlin, J.M.; Holt, H.K.; et al. Novel BAC mouse model of Huntington’s disease with 225 CAG repeats exhibits an early widespread and stable degenerative phenotype. J. Huntingt. Dis. 2015, 4, 17–36.
28. Tallaksen-Greene, S.J.; Sadagurski, M.; Zeng, L.; Mauch, R.; Perkins, M.; Banduseela, V.C.; Lieberman, A.P.; Miller, R.A.; Paulson, H.L.; Albin, R.L. Differential effects of delayed aging on phenotype and striatal pathology in a murine model of Huntington disease. J. Neurosci. 2014, 34, 15658–15668. [PubMed]
29. Graham, S.F.; Kumar, P.; Bahado-Singh, R.O.; Robinson, A.; Mann, D.; Green, B.D. Novel metabolite biomarkers of Huntington’s disease as detected by High-Resolution Mass Spectrometry. J. Proteome Res. 2016, 15, 1592–1601. [PubMed]
30. Satoh, T.; Yoshioka, Y. Contribution of reduced and oxidized glutathione to signals detected by magnetic resonance spectroscopy as indicators of local brain redox state. Neurosci. Res. 2006, 55, 34–39. [CrossRef] [PubMed]
31. Curtis, A.; Mitchell, I.; Patel, S.; Ives, N.; Rickards, H. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov. Disord. 2009, 24, 2254–2259. [CrossRef] [PubMed]
32. Curtis, A.; Rickards, H. Nabilone could treat chorea and irritability in Huntington’s disease. J. Neuropsychiatry Clin. Neurosci. 2006, 18, 553–554. [CrossRef] [PubMed]
33. Müller-Vahl, K.R.; Schneider, U.; Emrich, H.M. Nabilone increases choreatic movements in Huntington’s disease. Mov. Disord. 1999, 14, 1038–1040. [CrossRef]
34. Consroe, P.; Laguna, J.; Allender, J.; Snider, S.; Stern, L.; Sandyk, R.; Kennedy, K.; Schram, K. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol. Biochem. Behav. 1991, 40, 701–708. [CrossRef]
35. Petr, G.T.; Schultheis, L.A.; Hussey, K.C.; Sun, Y.; Dubinsky, J.M.; Aoki, C.; Rosenberg, P.A. Decreased expression of GLT-1 in the R6/2 model of Huntington’s disease does not worsen disease progression. Eur. J. Neurosci. 2013, 38, 2477–2490. [CrossRef] [PubMed]
36. Wade, D. Evaluation of the safety and tolerability profile of Sativex: Is it reassuring enough? Expert Rev. Neurother. 2012, 12, 9–14. [PubMed]
37. Ferrante, R.J.; Andreassen, O.A.; Jenkins, B.G.; Dedeoglu, A.; Kuemmerle, S.; Kubilus, J.K.; Kaddurah-Daouk, R.; Hersch, S.M.; Beal, M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J. Neurosci. 2000, 20, 4389–4397. [PubMed]
38. Andreassen, O.A.; Dedeoglu, A.; Ferrante, R.J.; Jenkins, B.G.; Ferrante, K.L.; Thomas, M.; Friedlich, A.; Browne, S.E.; Schilling, G.; Borchelt, D.R.; et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol. Dis. 2001, 8, 479–491. [CrossRef] [PubMed]
39. Tabrizi, S.J.; Blamire, A.M.; Manners, D.N.; Rajagopalan, B.; Styles, P.; Schapira, A.H.; Warner, T.T. Creatine therapy for Huntington’s disease: Clinical and MRS findings in a 1-year pilot study. Neurology 2003, 61, 141–142. [CrossRef] [PubMed]
40. 18F-FDG: Exemplified in a memantine pharmacological challenge. Neuroimage 2014, 96, 276–287. [CrossRef] [PubMed]